Efficacy and Safety of Telmisartan Compared With Losartan

Summary

A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension

Eligibility

Inclusion Criteria:

* Male of Female subjects aged ≥19 or \<75
* Type II Diabetes Mellitus subjects who have been taken medicine
* Subjects who have voluntarily decided to participate in this clinical trial and Signed ICF

Exclusion Criteria:

* Subjects with Type I Diabetes Mellitus
* Subjects with Primary hyper-aldosteronism
* Subjects with a history of drug or alcohol abuse or suspected patient within 1 year as of the time of screening
* Pregnant women, lactating women, or subjects who do not agree to use appropriate contraception during the clinical trial period
* Subjects who received other clinical trial drugs within 28 days of screening visit
* Subjects who are unable to participate in this clinical trial at the discretion of the investigator.

Conditions3

Interventions2

Related trials

• Losartan + Sunitinib in Treatment of Osteosarcoma — University of Colorado, Denver
• Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma — University of California, Davis
• A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) — Mayo Clinic
• Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial — University College, London
• Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer — Tyler J Curiel
• Telmisartan in Prostate Cancer — Tyler J Curiel

Browse More Trials